Effect of chronic albizzia julibrissin treatment on 5-hydroxytryptamine(1a) receptors in rat brain

Academic Article
uri icon

publication date

  • 2005

abstract

  • Quantitative receptor autoradiography and behavioral studies were employed to investigate whether the aqueous extract of Albizzia julibrissin (AEAJ) specifically targets serotonergic systems in rat brain. AEAJ was orally administered at 50 and 200 mg/kg to adult male SD rats for 7 days. Treatment with AEAJ (200 mg/kg) significantly increased time-spent in open arms and the number of open arm entries in an elevated plus-maze (EPM) versus saline controls (P<0.05). Moreover, those effects of AEAJ were blocked by WAY 100635, a 5-HT1A receptor antagonist. Following behavioral evaluation, the binding of [3H]8-hyroxy-2-(di-n-propylamino) tertalin ([3H]8-OH-DPAT) to 5-HT1A receptors in rat brain was investigated. [3H]8-OH-DPAT binding after AEAJ (200 mg/kg) treatment showed a marked increase in the frontal cortex, hippocampus (CA2 and CA3 regions) and in the lateral septum versus vehicle-treated controls. No changes of [3H]8-OH-DPAT binding were observed in the caudate putamen, dentate gyrus and CA1 areas of the hippocampus or in the hypothalamus. In the dorsal raphe region, [3H]8-OH-DPAT binding was significantly reduced by AEAJ (50 mg/kg) treatment but was unchanged by AEAJ (200 mg/kg). These results suggest that the anxiolytic-like effect of A. julibrissin is mediated by the changes of serotonergic nervous system, especially 5-HT1A receptors.